HomeBlogPeptide Reconstitution Calculator
Handling · Calculator

Peptide Reconstitution Calculator — Complete Vial Math for Every Stocked Compound

23 June 202613 min readREVIVE LAB UAE Research Desk
Peptide reconstitution calculator vial math UAE

Three formulas cover every scenario. This is the complete walkthrough — formulas, worked examples for every peptide REVIVE LAB UAE stocks, and the unit-conversion tables that make the syringe draw obvious.

For research use only. The doses in the worked examples are drawn from published research literature. They are not therapeutic recommendations.

1. The three master formulas

Internalise these three. Everything else is substitution.

Formula 1 — Concentration:
Concentration (mg/mL) = Vial mg ÷ Bac water mL added

Formula 2 — Volume per dose:
Volume (mL) = Desired dose (mg) ÷ Concentration (mg/mL)


Units (U-100) = Volume (mL) × 100

For micro-doses where the result is expressed in micrograms, do all calculations in μg:

Concentration (μg/mL) = Vial μg ÷ Bac water mL
Volume (mL) = Dose μg ÷ Concentration μg/mL
Units (U-100) = Volume × 100

Always keep the same mass unit on both sides of the division. Mixing mg and μg is the most common math error.

2. Worked example — Retatrutide

Vial: 5 mg. Bac water: 1 mL. Desired dose: 2 mg (Jastreboff phase 2 starting titration).

Full Jastreboff-anchored reconstitution sits in retatrutide reconstitution math.

3. Worked example — Tesamorelin

Vial: 10 mg. Bac water: 2 mL.

4. Worked example — BPC-157 (micro-dose math)

Vial: 5 mg = 5000 μg. Bac water: 2 mL. Desired dose: 250 μg (mid-range research dose).

The 10× check: If the answer feels wrong, multiply both top and bottom by 1000 to switch mg ↔ μg. The result must be the same. If it's not, you've mixed units.

5. Worked example — TB-500

Same micro-dose math as BPC-157. Vial: 5 mg. Standard research dose: 2 mg twice weekly (loading), then 2 mg weekly (maintenance).

6. Worked example — GHK-Cu

Vial: 50 mg or 100 mg. Topical formulations use different math (mg dissolved in g of vehicle for percentage).

7. Worked example — MOTS-c

8. Worked example — Semax (intranasal vs SC)

Vial: 10 mg. Russian clinical 0.1% formulation = 1 mg/mL.

The 10 mL reconstitution is preferred because it matches the published Russian intranasal clinical formulation concentration.

9. Worked example — NAD+ (larger doses)

Vial: 100 mg. Standard research SC dose: 50-100 mg per session.

NAD+ injections sting more than most peptides; dilute concentrations and slower push reduce site reaction. Full NAD+ context sits in NAD+ vs NMN vs NR.

10. The reverse calculation — solving for bac water volume

Sometimes you want to land a specific dose at exactly 50 U (the half-syringe sweet spot). Solve backwards:

Bac water (mL) = Vial mg × Volume desired (mL) ÷ Dose (mg)

Example: Want 250 μg of BPC-157 at exactly 50 U (0.5 mL) draw.
Bac water = 5000 μg × 0.5 mL ÷ 250 μg = 10 mL

11. Stability — how long can you keep the reconstituted vial?

PeptideRefrigerated stability (reconstituted)
Retatrutide28-30 days
Tesamorelin14 days reconstituted; freshly reconstituted weekly preferred
BPC-15728-30 days
TB-50028-30 days
GHK-Cu28 days (blue tint should remain; fade = degradation)
MOTS-c28-30 days
Semax28-30 days
NAD+14-21 days

12. UAE supply context

All peptides referenced above are stocked at REVIVE LAB UAE in HPLC-verified vials with lot-level COA. Bacteriostatic water UAE in 3 mL multi-dose vials ships in the same parcel.

Full catalogue at peptides UAE. Same-day Dubai dispatch on orders before 4 PM, 24 hours nationwide.

13. The summary

References

  1. Manning MC, Chou DK, Murphy BM, et al. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544-575. PubMed
  2. Vergote V, Burvenich C, Van de Wiele C, et al. Quality specifications for peptide drugs — a regulatory-pharmaceutical approach. J Pept Sci. 2009;15(11):697-710. PubMed
  3. Frokjaer S, Otzen DE. Protein drug stability: a formulation challenge. Nat Rev Drug Discov. 2005;4(4):298-306. PubMed
  4. Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-Hormone-Receptor Agonist Retatrutide. N Engl J Med. 2023;389(6):514-526. PubMed
  5. Falutz J, Allas S, Mamputu JC, et al. Long-term safety and effects of tesamorelin. J Clin Endocrinol Metab. 2010;95(9):4291-4304. PubMed
💰 Earn 20% commission on peptide sales
Share peptides with friends and earn USDT commissions on every order. Auto tier upgrades. No approval required — sign up in 60 seconds.
Join Affiliate →